LNSR News and Press, LENSAR Inc. From 08/08/22

LENSAR, Inc. (LNSR) Q2 2022 Earnings Conference Call August 08, 2022, 08:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Ryan Zimmer...

LENSAR press release ( NASDAQ: LNSR ): Q2 GAAP EPS of -$0.67. Revenue of $8M (+1.3% Y/Y). Adjusted EBITDA was -$4.3M for the quarter ended June 30, 2022 and -$2.3M for the quarter ended June 30, 2021. As of June 30, 2022, the company had cash and cash equivalents o...

Company Receives FDA Clearance of ALLY™ Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2022 financial resul...

LENSAR (NASDAQ:LNSR) stock jumped 10.5% premarket on Monday after the medical device maker received the U.S. Food and Drug Administration's 510(k) clearance for its ALLY adaptive cataract treatment system. ALLY is the first FDA-cleared platform to enable femtosecond-laser-assisted cataract su...

Day One Biopharmaceuticals (DAWN) +81% announces positive initial data from pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Redbox Entertainment (RDBX) +30%. Ekso Bionics Holdings (EKSO) +22% receives FDA clearance to market its EksoNR Robotic...

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration (“FDA”) 510(k...

The following slide deck was published by LENSAR, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: LENSAR, Inc. 2022 Q1 - Results - Earnings Call Presentation

LENSAR, Inc. (LNSR) Q1 2022 Earnings Conference Call May 9, 2022 8:30 a.m. ET Company Participants Cameron Radinovic - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Danielle Antalffy - SVB Presentat...

LENSAR press release (NASDAQ:LNSR): Q1 GAAP EPS of -$0.67 misses by $0.16. Revenue of $9.3M (+32.1% Y/Y) beats by $0.59M. For further details see: LENSAR GAAP EPS of -$0.67 misses by $0.16, revenue of $9.3M beats by $0.59M